retatrutide for diabetes Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA A new triple-action weekly injection

The analysis also includes tirzepatide (Mounjaro and Zepbound), which is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 agonist (and classified under A10BX or other blood glucose lowering drugs, excl

Incretin therapy is the second line of treatment for T2D, improving both blood glucose regulation and weight loss

Both groups were following diet and exercise guidance throughout, so its hard to separate the supplements effect from the lifestyle changesand with only 30 people per group, the findings are promising but far from definitive

Retatrutide promises to help the bodys metabolism work better